Chronic Kidney Disease, Hyperuricemia
Conditions
Keywords
allopurinol, chronic kidney disease, endothelial dysfunction, hyperuricemia, uric acid, vascular endothelium, xanthine oxidase inhibitor
Brief summary
In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.
Detailed description
Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.
Interventions
DRUGallopurinol
150 mg once a day
Sponsors
Istanbul University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Laboratory finding of hyperuricemia * Patients between ages of 18 and 60 years * Non-diabetic patients * Creatinine clearance values between 20 and 60 mL/min/1.73 m2
Exclusion criteria
* Low (\< 20 ml/min/1.73 m2) creatinine clearance, * Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack. * Patients taking urate lowering medication (allopurinol and probenecid)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endothelial function improvement with uric acid lowering treatment | 1 year |
Countries
Turkey (Türkiye)
Outcome results
None listed